MRI in children given gadodiamide injection: safety and efficacy in CNS and body indications.

Abstract

The safety and efficacy of the MRI contrast medium gadodiamide injection (OMNISCAN) in children is summarised. Four open and three double-blind, multinational, multicentre comparative trials have been undertaken. Overall, 353 patients (15 days to 18 years, plus one 21 years) received gadodiamide injection, and 128 (2-18 years) received gadopentetate dimeglumine (Magnevist), intravenously at 0.1 mmol/kg body weight, to aid the identification of CNS and body lesions. Adverse events were reported in 13 (4%) patients given gadodiamide injection and 8 (6%) given gadopentetate dimeglumine; few patients reported injection-associated discomfort. The post-contrast scan gave more diagnostic information in 223 (63%) patients given gadodiamide injection (CNS and body indications). In the comparative trials, the post-contrast scan gave more diagnostic information for 91 (65%) and 82 (64%) patients given gadodiamide injection and gadopentetate dimeglumine, respectively (CNS indications only). Gadodiamide injection (0.1 mmol/kg body weight) was safe and effective in infants, children and adolescents.

• Authors: B Lundby, P Gordon, F Hugo
• Journal: European journal of radiology (Eur J Radiol) Vol. 23 Issue 3 Pg. 190-6 (Nov 1996) ISSN: 0720-048X [Print] Ireland
• PMID: 9003923 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Contrast Media
• Drug Combinations
• Organometallic Compounds
• Meglumine
• Pentetic Acid
• gadodiamide
• Gadolinium
• Gadolinium DTPA

Topics

• Adolescent
• Central Nervous System Diseases (diagnosis)
• Child
• Child, Preschool
• Clinical Trials, Phase III as Topic
• Contrast Media
• Drug Combinations
• Gadolinium (adverse effects)
• Gadolinium DTPA
• Humans
• Infant
• Infant, Newborn
• Magnetic Resonance Imaging
• Meglumine (adverse effects)
• Multicenter Studies as Topic
• Organometallic Compounds (adverse effects)
• Pentetic Acid (adverse effects, analogs & derivatives)
• Randomized Controlled Trials as Topic
• Safety